GlassScriptPhysician profile
Leena Singh
NPI 1033172689
$7,916.63
in general payments reported to CMS, 2019-2025
42 companies · $1,365 in 2025
The $1,365 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $831 · 2020: $937 · 2021: $1,080 · 2022: $1,032 · 2023: $1,161 · 2024: $1,511 · 2025: $1,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,016 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,016.45 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $994.27 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $960.39 | 2019-2025 | Ozempic, Rybelsus, Sogroya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $823.03 | 2019-2025 | Jardiance, Ofev |
| Amgen INC. | $669.12 | 2020-2025 | Tepezza, Tavneos, Enbrel |
| Janssen Biotech, INC. | $496.38 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $464.14 | 2019-2024 | Synthroid |
| Mannkind Corporation | $395.95 | 2019-2025 | Afrezza |
| Astrazeneca Pharmaceuticals LP | $281.45 | 2019-2025 | Saphnelo |
| Bayer Healthcare Pharmaceuticals INC. | $269.30 | 2022-2025 | |
| Abbott Laboratories | $244.56 | 2019-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $236.32 | 2020-2025 | Benlysta |
| Genentech USA, INC. | $224.32 | 2019-2025 | Actemra, Gazyva |
| Sanofi-Aventis U.S. LLC | $169.30 | 2019-2025 | |
| Medtronic, INC. | $166.11 | 2023-2024 | Minimed 780g |
| Horizon Therapeutics Plc | $164.71 | 2021-2023 | Tepezza |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $147.10 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Merck Sharp & Dohme LLC | $132.46 | 2019-2021 | |
| Insulet Corporation | $107.58 | 2019-2023 | Omnipod |
| Aurinia Pharma U.S., INC. | $107.13 | 2022-2025 | Lupkynis |
| Almatica Pharma LLC | $95.33 | 2025 | Teriparatide |
| Ibsa Pharma INC. | $77.83 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $75.66 | 2020 | |
| Cequr Corporation | $61.82 | 2023-2025 | Cequr Simplicity |
| Ucb, INC. | $57.32 | 2024 | Cimzia |
| Corcept Therapeutics | $55.65 | 2019 | |
| Amarin Pharma, INC. | $42.48 | 2020-2021 | |
| Pfizer INC. | $41.04 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $36.40 | 2019-2020 | |
| Sequel Med Tech, LLC | $35.18 | 2025 | Twiist |
| Fresenius Kabi USA, LLC | $28.74 | 2024 | Idacio |
| Ani Pharmaceuticals, INC. | $28.33 | 2025 | Purified Cortrophin Gel |
| Kyowa Kirin, INC. | $25.57 | 2024 | Crysvita |
| Neurocrine Biosciences, INC. | $24.28 | 2025 | |
| Xeris Pharmaceuticals, INC. | $23.52 | 2025 | Recorlev |
| Alfasigma USA, INC. | $22.64 | 2021 | |
| Recordati_rare_diseases_inc. | $20.68 | 2022 | |
| Eusa Pharma (US) LLC | $20.68 | 2022 | |
| Shire North American Group INC | $20.05 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $18.68 | 2021 | |
| Celgene Corporation | $18.46 | 2019 | |
| Sun Pharmaceutical Industries INC. | $18.25 | 2020 | |
| Dexcom, INC. | $14.42 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leena Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.